Use of Diabetes Treatment Satisfaction Questionnaire in Diabetes Care: Importance of Patient-Reported Outcomes

Yoshifumi Saisho, Yoshifumi Saisho

Abstract

The efficacy of diabetes treatment should not be evaluated solely by HbA1c levels as they should also focus on patient-reported outcomes (PROs), such as patient satisfaction, wellbeing and quality of life. The Diabetes Treatment Satisfaction Questionnaire (DTSQ) has been developed to assess patient satisfaction with diabetes treatment. DTSQ has been translated into more than 100 languages and is widely used in many countries, since it is relatively easy to answer and is used for both patients with and without medical therapy. Novel therapeutic options, such as insulin analogs, incretin-based therapy and sodium-glucose cotransporter 2 (SGLT2) inhibitors, have been shown to improve patient satisfaction using DTSQ for assessments. DTSQ is not only used for comparisons between different medications or treatment strategies, but also can be used to assess the quality of diabetes care in clinical settings. This is important as an improvement in treatment satisfaction may enhance patients' self-efficacy and adherence to therapy, leading to the achievement of long-term stable glycemic control and reduced risk of diabetic complications. In this review, we summarize the current topics in DTSQ, introducing our own experience, and discuss the role of PROs in diabetes treatment.

Keywords: ceiling effect; patient-reported outcome; quality of life; treatment satisfaction.

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Factors associated with treatment satisfaction and expected effects from its improvement on clinical outcomes.

References

    1. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008;359:1577–1589. doi: 10.1056/NEJMoa0806470.
    1. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., Raskin P., Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005;353:2643–2653.
    1. Shichiri M., Kishikawa H., Ohkubo Y., Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23:B21–B29.
    1. American Diabetes Association Glycemic Targets: Standards of Medical Care in Diabetes—2018. Diabetes Care. 2018;41:S55–S64.
    1. International Diabetes Federation Guideline Development Group Global Guideline for Type 2 Diabetes. Diabetes Res. Clin. Pract. 2014;104:1–52.
    1. Bradley C., Speight J. Patient perceptions of diabetes and diabetes therapy: Assessing quality of life. Diabetes Metab. Res. Rev. 2002;18:S64–S69. doi: 10.1002/dmrr.279.
    1. Speight J., Reaney M.D., Barnard K.D. Not all roads lead to Rome-a review of quality of life measurement in adults with diabetes. Diabet. Med. 2009;26:315–327. doi: 10.1111/j.1464-5491.2009.02682.x.
    1. Davies M., Speight J. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2012;14:882–892. doi: 10.1111/j.1463-1326.2012.01595.x.
    1. Roborel de Climens A., Tunceli K., Arnould B., Germain N., Iglay K., Norquist J., Brodovicz K.G. Review of patient-reported outcome instruments measuring health-related quality of life and satisfaction in patients with type 2 diabetes treated with oral therapy. Curr. Med. Res. Opin. 2015;31:643–665. doi: 10.1185/03007995.2015.1020364.
    1. Bradley C., Gamsu D.S. Guidelines for encouraging psychological well-being: Report of a Working Group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes. Diabet. Med. 1994;11:510–516. doi: 10.1111/j.1464-5491.1994.tb00316.x.
    1. Ishii H., Bradley C., Riazi A., Barendse S., Yamamoto T. The Japanese version of the diabetes treatment satisfaction questionnaire (DTSQ): Translation and clinical evaluation. J. Clin. Exp. Med. 2000;192:809–814.
    1. Hartman I. Insulin analogs: Impact on treatment success, satisfaction, quality of life, and adherence. Clin. Med. Res. 2008;6:54–67. doi: 10.3121/cmr.2008.793.
    1. Home P.D., Lindholm A., Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: A randomized controlled trial. Diabet. Med. 2000;17:762–770. doi: 10.1046/j.1464-5491.2000.00380.x.
    1. Ashwell S.G., Bradley C., Stephens J.W., Witthaus E., Home P.D. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care. 2008;31:1112–1117. doi: 10.2337/dc07-1183.
    1. Lind M., Jendle J., Torffvit O., Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim. Care Diabetes. 2012;6:41–46. doi: 10.1016/j.pcd.2011.09.002.
    1. Sato S., Saisho Y., Kou K., Meguro S., Tanaka M., Irie J., Kawai T., Itoh H. Efficacy and Safety of Sitagliptin Added to Insulin in Japanese Patients with Type 2 Diabetes: The EDIT Randomized Trial. PLoS ONE. 2015;10:e0121988. doi: 10.1371/journal.pone.0121988.
    1. Rodbard H.W., Peters A.L., Slee A., Cao A., Traina S.B., Alba M. The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes. Diabetes Care. 2017;40:171–180. doi: 10.2337/dc16-1353.
    1. Hutchins V., Zhang B., Fleurence R.L., Krishnarajah G., Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr. Med. Res. Opin. 2011;27:1157–1168. doi: 10.1185/03007995.2011.570745.
    1. Best J.H., Boye K.S., Rubin R.R., Cao D., Kim T.H., Peyrot M. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet. Med. 2009;26:722–728. doi: 10.1111/j.1464-5491.2009.02752.x.
    1. Saisho Y., Itoh H. Factors associated with treatment satisfaction in patients with type 2 diabetes. Practice. 2015;32:100–107. (In Japanese)
    1. Saisho Y., Itoh H. Relationship between treatment satisfaction and intention to drop out in outpatients with type 2 diabetes. J. Jpn. Diabetes Soc. 2012;55:768–773. (In Japanese)
    1. Taylor R., Foster B., Kyne-Grzebalski D., Vanderpump M. Insulin regimens for the non-insulin dependent: Impact on diurnal metabolic state and quality of life. Diabet. Med. 1994;11:551–557. doi: 10.1111/j.1464-5491.1994.tb02034.x.
    1. Bradley C. Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care. 1999;22:530–532. doi: 10.2337/diacare.22.3.530.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren